Furthermore, silymarin can reduce steatosis and insulin resistance seen in NAFLD through restoration of the insulin receptor substrate-1 (IRS-1)/PI3K/Akt pathway [12]. The gene discussed is IRS1; the disease is metabolic dysfunction-associated steatotic liver disease.